Metformin Beyond Type 2 Diabetes Mellitus (2024) Rahnuma Ahmad

Description

This narrative review examines Metformin’s effectiveness beyond its primary use in Type 2 Diabetes Mellitus, focusing specifically on non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, and various carcinomas. The mechanisms discussed include reducing reactive oxygen species, improving insulin sensitivity, and enhancing hepatic cell lipophagy. The review emphasizes the need for further research, guideline development for liver diseases incorporating metformin, and pharmacovigilance regarding long-term adverse effects.